The CGCN Group, a Republican lobbying firm, tells STAT that the Alliance to Protect Medical Innovation, a new pro-pharma advocacy group, is one of their clients.
According to STAT, the group on Thursday said it had received “seed money from people inside the [drug] industry.”
CGCN Group Partner Ken Spain says his organization is “helping [APMI] with the rollout of the organization.”
APMI has taken a firm stance against efforts to bring down prescription drug costs, denouncing “short-sighted policy proposals that would chill investment in biomedical research and stifle future innovation … .”
BIO, a brand drug lobby, announced Thursday it would become one of APMI’s first members, according to STAT.